The field of diabetes is constantly evolving, with numerous new molecules reaching the market for the treatment of type 2 diabetes. Paradoxically, this drug jungle is difficult for the primary care physician and can lead to therapeutic inertia. The aim of this article is to discuss new molecules and new cardiovascular outcome studies that lead to changes in guidelines pertinent to the pharmacological treatment of type 2 diabetes.